Xeris Biopharma Holdings Inc (NASDAQ: XERS) kicked off on Thursday, up 0.74% from the previous trading day, before settling in for the closing price of $4.08. Over the past 52 weeks, XERS has traded in a range of $1.69-$6.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 197.66% over the past five years. While this was happening, its average annual earnings per share was recorded 83.57%. With a float of $141.94 million, this company’s outstanding shares have now reached $149.43 million.
Let’s look at the performance matrix of the company that is accounted for 394 employees. In terms of profitability, gross margin is 79.19%, operating margin of -16.57%, and the pretax margin is -28.12%.
Xeris Biopharma Holdings Inc (XERS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Xeris Biopharma Holdings Inc is 7.80%, while institutional ownership is 42.82%. The most recent insider transaction that took place on Mar 20 ’25, was worth 217,244. In this transaction an insider of this company sold 40,000 shares at a rate of $5.43, taking the stock ownership to the 1,353,510 shares. Before that another transaction happened on Mar 20 ’25, when Company’s Officer proposed sale 40,000 for $5.14, making the entire transaction worth $205,600.
Xeris Biopharma Holdings Inc (XERS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 83.57% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Take a look at Xeris Biopharma Holdings Inc’s (XERS) current performance indicators. Last quarter, stock had a quick ratio of 1.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach 0.12 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Xeris Biopharma Holdings Inc (NASDAQ: XERS) saw its 5-day average volume 2.08 million, a negative change from its year-to-date volume of 2.74 million. As of the previous 9 days, the stock’s Stochastic %D was 37.41%. Additionally, its Average True Range was 0.34.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 35.74%, which indicates a significant increase from 17.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.93% in the past 14 days, which was higher than the 57.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.41, while its 200-day Moving Average is $3.34. Nevertheless, the first resistance level for the watch stands at $4.19 in the near term. At $4.28, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.35. If the price goes on to break the first support level at $4.03, it is likely to go to the next support level at $3.96. The third support level lies at $3.87 if the price breaches the second support level.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
The company with the Market Capitalisation of 632.69 million has total of 153,940K Shares Outstanding. Its annual sales at the moment are 203,070 K in contrast with the sum of -54,840 K annual income. Company’s last quarter sales were recorded 60,100 K and last quarter income was -5,110 K.
